Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503330 | 0.82 | MTNR1B (0.43) | — | |
| SCHEMBL4521719 | 0.82 | HPGDS (0.40) | KCNH2GRIN1 | |
| SCHEMBL5503532 | 0.81 | IRAK4 (0.41) | KCNH2 | |
| SCHEMBL4793670 | 0.79 | LMNA (0.36) | KCNH2RORCMALT1 | |
| SCHEMBL5509173 | 0.78 | MTNR1B (0.41) | — | |
| SCHEMBL5506070 | 0.74 | MTNR1B (0.52) | — | |
| SCHEMBL4509721 | 0.73 | NPC1 (0.41) | KCNH2SRCMALT1 | |
| SCHEMBL447794 | 0.71 | MALT1 (0.41) | KCNH2SRCMALT1 | |
| SCHEMBL5503277 | 0.69 | MTNR1B (0.41) | KCNH2 | |
| SCHEMBL5507816 | 0.68 | KCNH2 (0.44) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | KCNH2 1951/4885SRC 3966/4885ABCB1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.